Branchio-Oculo-Facial Syndrome (BOFS)

Branchio-Oculo-Facial Syndrome (BOFS) is a very rare genetic condition that affects the skin and tissues of the neck (“branchio-”), the eyes (“oculo-”), and the face (“facial”). Most babies with BOFS show signs at birth. The condition is usually caused by a change (mutation) in a single gene called TFAP2A, which makes a control protein (a transcription factor) that switches other genes on and off during early development. When TFAP2A does not work properly, parts of the head and neck do not form in the usual way. BOFS is typically inherited in an autosomal dominant pattern, but many cases are new (de novo) in the child. NCBI+2MedlinePlus+2

Branchio-oculo-facial syndrome (BOFS) is a rare, usually autosomal-dominant genetic condition caused by pathogenic variants in the TFAP2A gene. It mainly affects the neck/branchial region, the eyes, and the face—producing characteristic skin defects near the ears or neck, eye abnormalities (such as microphthalmia, coloboma, or blocked tear ducts), and distinctive facial features (including cleft or “pseudocleft” of the upper lip, and sometimes cleft palate). Hearing loss, kidney anomalies, and growth differences may also occur. Diagnosis is clinical and confirmed with TFAP2A testing; care is lifelong and multidisciplinary. NCBI+2MedlinePlus+2

TFAP2A encodes the transcription factor AP-2α, a master switch that turns many developmental genes on or off. Faults in TFAP2A disrupt normal formation of the branchial arches and ocular/craniofacial structures during early embryogenesis, explaining the triad of branchial, ocular, and facial findings. Pathogenic variants cluster in the DNA-binding domain and reduce AP-2α’s ability to regulate downstream targets. MedlinePlus+2PMC+2

Doctors recognize BOFS by a mix of findings that commonly include: patchy or eroded skin in the side of the neck near the ears (from branchial cleft areas), eye differences (such as small eyes, coloboma, blocked tear ducts, or cataract), and facial features such as a cleft lip/palate or a “pseudocleft” of the upper lip with a broad nasal tip. Hearing differences, hair changes, and occasionally kidney differences may also be present. NCBI+2NCBI+2

Other Names

Doctors and articles may use different names for the same condition. You might see:

• Branchiooculofacial syndrome (no hyphens; common medical spelling). NCBI

• Hemangiomatous branchial clefts–lip pseudocleft syndrome (historical descriptive name). Wikipedia

• BOFS (the usual short name in clinics and genetics sources). NCBI

Types

There is no strict “type 1, 2, 3” system for BOFS. Instead, doctors discuss phenotypic variation—that is, the condition ranges from mild to severe across three main areas (neck/branchial, eyes, and face). Some papers use terms such as “typical BOFS” when the classic triad is present and “atypical BOFS” when only one system (for example, only an eye coloboma) appears and genetic testing finds a TFAP2A variant. Families may also show different features even with the same gene change. NCBI+1

Causes

Each “cause” below explains a known or proposed reason the syndrome looks the way it does. Many are closely related, because they stem from the TFAP2A gene not working normally.

1. Pathogenic variants in TFAP2A
   A change in the TFAP2A gene is the main, proven cause of BOFS. This change alters the AP-2α protein so it cannot bind DNA and control embryonic genes correctly. PubMed+1

2. De novo TFAP2A variants
   Many children have a new (not inherited) mutation that arose in the egg or sperm or very early after fertilization. PubMed

3. Autosomal dominant inheritance
   If a parent has BOFS (and the TFAP2A variant), there is a 1-in-2 chance in each pregnancy to pass it on. PubMed

4. DNA-binding domain disruption
   Most TFAP2A mutations cluster in exons coding for the basic DNA-binding region, directly blocking gene regulation in early head/neck development. PubMed+1

5. Haploinsufficiency
   Having only one working copy of TFAP2A may be insufficient (“haploinsufficient”) for normal development, leading to the BOFS phenotype. NCBI

6. Transcriptional network imbalance
   AP-2α regulates many downstream genes. When AP-2α falters, multiple tissues—skin, branchial arches, eyes, and craniofacial structures—develop abnormally. MedlinePlus

7. Branchial arch patterning errors
   TFAP2A helps pattern the branchial (pharyngeal) arches. Faulty patterning explains neck skin defects, pits, and fistulas. NCBI

8. Ocular morphogenesis errors
   AP-2α is important for eye formation. Disrupted signaling can produce coloboma, microphthalmia, cataract, or tear-duct blockage. NCBI

9. Craniofacial midline and lip formation errors
   AP-2α influences lip and palate fusion. Disturbance may cause cleft lip/palate or a pseudocleft with prominent philtral pillars. NCBI

10. Abnormal ectodermal development
    Hair, skin, nails, and lacrimal ducts derive from ectoderm. TFAP2A changes can lead to patchy neck skin, hair tufts, and lacrimal obstruction. NCBI

11. External/middle ear maldevelopment
    Branchial arch and pouch errors can affect pinna shape and middle-ear bones, causing conductive hearing loss. NCBI

12. Inner ear anomalies (less common)
    Occasionally, inner ear structures are affected, producing sensorineural hearing loss. NCBI

13. Facial nerve involvement
    Some children have asymmetric crying or partial facial nerve weakness from developmental anomalies. NCBI

14. Renal/urinary tract anomalies (in a minority)
    Kidney differences have been reported in some patients, likely reflecting broader developmental effects. Wikipedia

15. Growth restriction
    Some reports describe low birth weight or slower growth, likely secondary to systemic developmental differences. monarchinitiative.org

16. Variable expressivity
    The same TFAP2A change can look different in different people, because other genes and environmental factors modify the outcome. NCBI

17. Reduced penetrance (rare)
    A few individuals with a variant may show mild or few features, which can obscure family history. Wikipedia

18. Mosaicism (possible)
    Very rarely, a parent can be mosaic (the variant is in some cells but not others), which can explain an apparently “new” case. (General genetic principle discussed in GeneReviews for many dominant syndromes.) NCBI

19. Structural TFAP2A variants
    Rarely, small deletions/duplications or complex changes in TFAP2A may alter protein function and cause BOFS. NCBI

20. Novel missense variants with experimental support
    Recent case reports describe new TFAP2A substitutions supported by protein modeling and family studies, expanding the known variant spectrum. Nature+2Frontiers+2

Symptoms and Signs

1. Neck/near-ear skin defects (branchial cleft lesions)
   Thin, reddish “hemangioma-like” patches or weeping erosions occur around the side of the neck and near or behind the ears. These reflect abnormal healing and skin formation where branchial tissues emerge. NCBI

2. Pits, sinuses, or fistulas in the neck region
   Small openings or tracts may be present and can leak or get infected. They form because the branchial arches did not fuse as expected. NCBI

3. Blocked tear ducts (nasolacrimal duct stenosis/atresia)
   Tears may overflow (“watering eyes”) because the drainage tube is narrow or closed. This is common in BOFS and sometimes needs a procedure. NCBI

4. Eye coloboma or microphthalmia
   A coloboma is a gap in structures like the iris or retina; microphthalmia means a small eye. Either can reduce vision and may be unilateral or bilateral. NCBI

5. Cataract
   Clouding of the lens can be present at birth or early in life and may require surgery to protect sight. NCBI

6. Cleft lip and/or cleft palate
   A true cleft or a “pseudocleft” (prominent philtral pillars that mimic a repaired cleft) can affect feeding, speech, and dental alignment and often needs team care. NCBI

7. Broad nasal tip and up-slanting eye openings
   These facial features are common descriptive clues that help clinicians recognize the syndrome pattern. NCBI

8. Upper-lip pits
   Small depressions on the upper lip can occur and are part of the facial feature set in BOFS. NCBI

9. Ear shape anomalies and hearing loss
   The outer ear may be rotated or misshapen; fused or malformed middle-ear bones can reduce sound conduction. Inner ear differences are less common but can cause sensorineural loss. NCBI

10. Lower facial weakness (asymmetric crying face)
    Some babies have mild facial nerve weakness, more noticeable when crying, affecting the symmetry of the mouth. NCBI

11. Dental and jaw differences
    Crowding, malocclusion, and maxillary issues may appear due to the overall craniofacial pattern. (Summarized across clinical series.) NCBI

12. Hair and skin changes
    Areas of thin skin or tufted hair can occur around neck lesions. These are ectodermal findings linked to TFAP2A function. NCBI

13. Speech and feeding difficulties
    Cleft palate, dental issues, and ear/hearing problems can combine to delay speech or make feeding challenging in infancy. (GeneReviews clinical management notes.) NCBI

14. Kidney/urinary tract anomalies (occasionally)
    A minority of individuals show renal differences; screening is often advised because early signs can be silent. Wikipedia

15. Growth differences and developmental variability
    Some reports note low birth weight or slower growth; learning or developmental profiles vary and are not uniform across all cases. monarchinitiative.org

Diagnostic Tests

Important note: Diagnosis is clinical plus genetic. Doctors first look for the pattern of features and then confirm with a DNA test for TFAP2A. Testing also checks for other causes when the picture is unclear. NCBI

A) Physical Examination

1. Full newborn and pediatric exam focused on head and neck
   The clinician looks for neck skin lesions near the ears, branchial pits/sinuses, ear shape, facial symmetry, and lip/palate differences. Skin lesions in BOFS often look hemangioma-like and may be wet or eroded. NCBI

2. Ophthalmologic inspection at the bedside
   A penlight and ophthalmoscope look for microphthalmia, iris coloboma, cataract, and tearing from blocked ducts. Early detection protects vision. NCBI

3. Otolaryngologic (ENT) exam
   External ear shape, ear canal, and eardrum are checked; sinuses/fistulas in the neck are mapped, and signs of infection are noted. NCBI

4. Craniofacial and dental exam
   Cleft lip/palate, pseudocleft, malocclusion, and palate function are reviewed, often by a craniofacial team. NCBI

5. Neurologic and facial nerve assessment
   The examiner checks facial movement for asymmetric crying or lower facial weakness and screens tone and reflexes as part of the baseline. NCBI

B) Manual / Bedside Tests

6. Tear-duct patency test (fluorescein dye disappearance)
   A drop of dye is placed in the eye; delayed clearance suggests nasolacrimal obstruction common in BOFS. NCBI

7. Fistula probing during ENT evaluation
   Gentle probing helps define the course of a neck sinus or fistula for future surgery and reduces the risk of incomplete repair. NCBI

8. Bedside hearing screening (otoacoustic emissions in newborns)
   Quick, noninvasive screening can flag conductive or sensorineural hearing problems for full audiology follow-up. NCBI

9. Feeding and speech assessment
   Simple functional checks for suck, swallow, nasal regurgitation, and early sound production help decide on therapy needs in infants with cleft/palate issues. NCBI

C) Laboratory / Pathological Tests

10. Molecular genetic testing of TFAP2A
    This is the key confirmatory test. Sequencing looks for single-letter changes; deletion/duplication analysis looks for small missing or extra pieces. A pathogenic variant confirms the diagnosis. NCBI+1

11. Targeted familial testing
    If the child has a known TFAP2A variant, parents and siblings can be tested to clarify inheritance and recurrence risk. PubMed

12. Prenatal or preimplantation genetic testing (when indicated)
    Families with a known TFAP2A variant may consider these options in future pregnancies. PubMed

13. Broader gene panel or exome testing (when BOFS is uncertain)
    If the picture is not classic, clinicians may order a craniofacial/ocular gene panel or exome to rule out similar disorders (e.g., branchio-oto-renal syndrome). NCBI

14. Basic labs when infections or wound issues are present
    If a neck lesion is draining, cultures and routine labs can guide antibiotics before or after surgery; this is supportive care, not diagnostic of BOFS itself. (General clinical practice; GeneReviews notes on lesion care.) NCBI

D) Electrodiagnostic / Functional Tests

15. Formal audiology with tympanometry
    Auditory brainstem response (ABR) or behavioral audiometry plus tympanometry define conductive versus sensorineural loss and guide hearing support. NCBI

16. Visual electrophysiology (ERG/VEP) when retinal involvement is suspected
    If a coloboma or other retinal issue is present, ERG/VEP assesses retinal and visual pathway function to plan follow-up. (Standard ophthalmic practice in structural eye disorders.) NCBI

17. Facial nerve studies (rarely needed)
    If facial weakness is significant or atypical, nerve conduction/electromyography may be used, mainly to document baseline. (General neurologic practice.) NCBI

E) Imaging Tests

18. High-resolution temporal bone CT or MRI
    These studies map the middle and inner ear for surgical planning and to understand the cause of hearing loss. NCBI

19. Ocular imaging (ultrasound, OCT, MRI when indicated)
    Eye ultrasound can assess microphthalmia and cataract in infants; OCT images the retina in older children if coloboma or other defects are suspected. NCBI

20. Renal ultrasound
    Because kidney anomalies can occur in BOFS, a screening renal ultrasound is often performed to catch silent differences early. Wikipedia

Non-Pharmacological Treatments (therapies & other supports)

1. Multidisciplinary care coordination
   Description. A care team led by genetics coordinates ENT, ophthalmology, craniofacial surgery, audiology, speech-language therapy, dentistry, and nephrology as needed. Regular team reviews prevent gaps in care and help time surgeries with growth and development. Purpose. Streamline complex, lifelong needs, reduce repeated anesthesia episodes, and align goals with family priorities. Mechanism. Team-based planning integrates findings from hearing tests, slit-lamp exams, palate assessments, and imaging, then sequences interventions (e.g., lacrimal procedures before school, palate repair before speech sounds develop). NCBI

2. Early vision care and amblyopia prevention
   Description. Pediatric ophthalmologists monitor for microphthalmia, coloboma, cataract, refractive error, and tear-duct blockage. Patching the stronger eye or using glasses can prevent “lazy eye.” Purpose. Preserve the best possible vision in the eye with potential. Mechanism. Early correction reduces unequal input to the brain’s visual cortex, lowering amblyopia risk; managing tear-duct blockage reduces infection and tearing that can degrade vision. MedlinePlus

3. Eye surface protection and hygiene training
   Description. Families learn lid hygiene, warm compresses, lash care, and blinking strategies, especially if nasolacrimal obstruction or exposure risk exists. Purpose. Reduce conjunctivitis, keratitis, and discomfort from tear-film instability. Mechanism. Mechanical cleansing and warmth helps unclog secretions; habit training optimizes tear distribution over the cornea when blinking is incomplete due to facial weakness. NCBI

4. Speech-language therapy
   Description. A therapist evaluates feeding and later speech, especially with cleft/pseudocleft or palatal insufficiency. Purpose. Support safe swallowing, normal resonance, articulation, and language. Mechanism. Targeted exercises and compensatory strategies strengthen or redirect airflow and articulation; therapists coordinate with surgeons to time palate repair for optimal speech development. NCBI

5. Audiology and hearing rehabilitation
   Description. Routine newborn screen follow-up plus diagnostic audiology (ABR/OAE) and middle-ear evaluation. Purpose. Detect conductive or sensorineural loss early and provide hearing aids or bone-anchored devices as needed. Mechanism. Amplification restores audibility of speech sounds during critical language windows; medical/surgical middle-ear care treats conductive components. NCBI

6. Feeding support and nutrition counseling
   Description. Infants with cleft or palatal dysfunction may need special bottles, thickened feeds, or supervised swallowing strategies; later, dietitians monitor growth. Purpose. Maintain growth and reduce aspiration risk. Mechanism. Tailored nipple/flow rates reduce nasopharyngeal regurgitation; dietetic plans prevent malnutrition in children with multiple procedures. NCBI

7. Craniofacial orthodontic planning
   Description. As teeth erupt, orthodontists plan arch alignment and maxillary growth support. Purpose. Optimize occlusion and facial balance, often around cleft repair timelines. Mechanism. Growth-guided appliances and staged orthodontics prepare for alveolar bone grafting and improve mastication and speech articulation. NCBI

8. Scar and skin-lesion wound care
   Description. For branchial skin erosions/“hemangiomatous” patches, clinicians use dressings, infection prevention, and staged excision planning. Purpose. Prevent infection and reduce chronic weeping while planning definitive surgical care. Mechanism. Moist-wound care with gentle cleansing and occlusive dressings supports re-epithelialization; surveillance times surgery to minimize recurrence. NCBI

9. Vision assistive technologies
   Description. Low-vision evaluation may provide magnifiers, high-contrast materials, screen readers, and classroom supports. Purpose. Maximize academic and daily living independence. Mechanism. Optical and digital aids compensate for acuity loss or field defects from coloboma/cataract. MedlinePlus

10. Educational plans (IEPs/504)
    Description. With hearing/vision differences, schools develop individual plans for seating, captioning, and extra time. Purpose. Ensure equal access to learning. Mechanism. Acoustic/visual accommodations offset sensory gaps and fatigue from repeated medical visits. NCBI

11. Psychosocial support and counseling
    Description. Families often face uncertainty and body-image concerns; counseling and peer support reduce stress. Purpose. Improve resilience, treatment adherence, and quality of life. Mechanism. Coping skills and support networks buffer chronic-care burdens common in rare genetic disorders. globalgenes.org

12. Genetic counseling
    Description. Counselors explain inheritance, recurrence risks, and reproductive options (e.g., prenatal or IVF-PGT). Purpose. Informed decision-making for present and future pregnancies. Mechanism. Translating molecular results into family-specific risk estimates empowers planning. NCBI

13. Renal surveillance protocols
    Description. Baseline and periodic kidney ultrasound and urinalysis if anomalies are suspected. Purpose. Early detection of structural or functional changes. Mechanism. Imaging and labs look for hydronephrosis or scarring that may be silent early on. Wikipedia

14. Sun and skin protection routines
    Description. Gentle cleansers, fragrance-free emollients, and sun protection on thin or repaired skin areas. Purpose. Limit irritation and hyperpigmentation on previously eroded patches. Mechanism. Barrier support and UV protection reduce inflammation and scarring. NCBI

15. Infection-prevention teaching
    Description. Families learn signs of ear, eye, and skin infection and when to seek care. Purpose. Prompt treatment prevents complications and hearing/vision loss. Mechanism. Early recognition and hygiene practices interrupt pathogen spread at vulnerable sites. NCBI

16. Lacrimal massage & warm compresses
    Description. For partial tear-duct blockage in infants, parents can perform gentle Crigler massage and warm compresses. Purpose. Improve drainage and reduce tearing/infection while awaiting definitive procedures. Mechanism. Mechanical pressure can open membranous obstruction at the valve of Hasner. MedlinePlus

17. Developmental surveillance
    Description. Regular screens for motor, language, and social milestones with early referral if delays emerge. Purpose. Ensure timely therapies to close developmental gaps. Mechanism. Standardized tools (e.g., ASQ) detect delays that may stem from sensory loss or repeated procedures. Genetic Rare Diseases Info Center

18. Dental and oral-health programs
    Description. Early dental home, fluoride, and caries prevention around cleft/palatal issues. Purpose. Protect enamel and support speech and feeding. Mechanism. Preventive dentistry reduces reconstructive burdens and supports orthodontic plans. NCBI

19. Perioperative airway planning
    Description. Anesthesia teams anticipate airway differences in craniofacial anomalies. Purpose. Make surgeries safer and reduce airway complications. Mechanism. Preop airway assessment and specialized equipment improve intubation success. NCBI

20. Transition planning to adult care
    Description. As teens mature, the team prepares them to manage appointments, devices, and medications. Purpose. Preserve continuity and independence. Mechanism. Structured transition clinics hand off to adult ENT, ophthalmology, dentistry, and genetics. globalgenes.org

---

Drug Treatments

BOFS has no disease-specific, curative drug. Medicines below are commonly used to manage associated problems (eye infections, ear infections, inflammation, pain, reflux, etc.). Dosing always individualized by clinicians—especially in infants/children.

1. Ciprofloxacin ophthalmic solution (Ciloxan®) 0.3%
   Class. Fluoroquinolone antibiotic. Typical use & timing. Bacterial conjunctivitis/keratitis: multiple daily instillations for days to weeks per label. Purpose. Treat susceptible ocular infections, often in eyes with tear-duct problems or exposure risk. Mechanism. Inhibits bacterial DNA gyrase/topoisomerase IV. Common side effects. Local burning, crystalline precipitates (keratitis regimens). Example dosing. Per label schedules (e.g., frequent drops initially then taper). Evidence. FDA label details spectrum, dosing, and safety. FDA Access Data

2. Ciprofloxacin ophthalmic ointment 0.3%
   Class. Fluoroquinolone antibiotic. Use. Nighttime coverage for conjunctivitis/keratitis. Purpose. Prolonged contact time to protect cornea during sleep. Mechanism. Same as solution; ointment base extends residence. Effects. Temporary blurred vision, irritation. Evidence. FDA label. FDA Access Data

3. Ofloxacin ophthalmic solution (Ocuflox®) 0.3%
   Class. Fluoroquinolone antibiotic. Use. Bacterial conjunctivitis/corneal ulcers with label-directed frequent dosing. Purpose. Alternative to ciprofloxacin based on culture/sensitivity. Mechanism/Effects. Fluoroquinolone class effects; local irritation possible. Evidence. FDA label. FDA Access Data

4. Ofloxacin otic solution (Floxin® Otic) 0.3%
   Class. Fluoroquinolone antibiotic. Use. Otitis externa/media with perforation or tubes—relevant when ear anomalies raise infection risk. Mechanism. Bactericidal via DNA gyrase/topoisomerase IV. Side effects. Pruritus, taste per label. Dosing. Label-based ear-drop schedules. Evidence. FDA label. FDA Access Data+1

5. Amoxicillin (immediate-release)
   Class. Aminopenicillin. Use. First-line for many pediatric ENT infections when appropriate. Purpose. Treat bacterial otitis media/sinusitis per guidelines. Mechanism. Inhibits cell-wall synthesis. Adverse effects. GI upset, rash. Dosing. Weight-based mg/kg/day split dosing per label/standard practice. Evidence. FDA labeling (AMOXIL). FDA Access Data+1

6. Amoxicillin extended-release (Moxatag®)
   Class. Aminopenicillin, ER. Use. Once-daily pharyngitis and selected infections when ER dosing fits adherence needs. Mechanism/Effects. As above; ER kinetics allow daily dosing. Evidence. FDA label. FDA Access Data

7. Cephalexin
   Class. First-generation cephalosporin. Use. Skin/soft tissue infections around branchial lesions or post-op prophylaxis if indicated. Mechanism. Cell-wall synthesis inhibition. Side effects. GI upset, hypersensitivity. Dosing. Weight-based; adult 250–500 mg q6h typical per label. Evidence. FDA labels (Keflex). FDA Access Data+2FDA Access Data+2

8. Prednisolone acetate ophthalmic (e.g., Pred Forte®, Omnipred®)
   Class. Ophthalmic corticosteroid. Use. Steroid-responsive anterior segment inflammation after ocular procedures or exposure keratopathy (with close supervision). Purpose. Reduce inflammation/edema; Mechanism. Inhibits phospholipase A2 pathway. Risks. IOP rise, infection flare, cataract—use only when indicated with monitoring. Evidence. FDA labels. FDA Access Data+1

9. Gentamicin + prednisolone ophthalmic (Pred-G®)
   Class. Antibiotic + steroid combo. Use. When steroid is indicated and superficial infection risk exists. Mechanism. Aminoglycoside coverage plus anti-inflammatory effect. Risks. Delayed healing, IOP rise; use judiciously. Evidence. FDA labels (suspension/ointment). FDA Access Data+1

10. Timolol ophthalmic gel/solution
    Class. Topical beta-blocker for glaucoma. Use. If secondary glaucoma develops after eye surgery or steroid use. Mechanism. Lowers aqueous humor production. Cautions. Asthma/COPD and bradycardia contraindications. Evidence. FDA labels (Timoptic-XE, Timolol GFS). FDA Access Data+1

11. Erythromycin ophthalmic ointment (class note)
    Note. While classic ophthalmic erythromycin labeling is discussed in FDA reviews, clinicians commonly use it as nighttime lubricant/antibiotic prophylaxis in exposure or duct-obstruction settings; confirm current local labeling. Mechanism. Macrolide; protein synthesis inhibition. Evidence. FDA clinical documentation regarding ophthalmic erythromycin. FDA Access Data

12. Analgesics (acetaminophen/ibuprofen)
    Class. Analgesic/NSAID. Use. Post-procedure pain control to maintain hydration and sleep. Mechanism. Central COX (acetaminophen) and COX inhibition (ibuprofen). Cautions. Weight-based dosing; renal/GI cautions for NSAIDs. Evidence. FDA labels exist for branded forms; dosing per pediatric standards under clinician guidance. FDA Access Data

13. Topical antibiotic skin therapy (as indicated)
    Class. Various (e.g., mupirocin/others per local protocols). Use. Minor secondary infection around lesions. Mechanism. Suppress susceptible skin flora. Evidence. FDA labels for specific products; use only if clinically indicated. FDA Access Data

14. Acid suppression for reflux (adjunct when aspiration risk)
    Class. H2RA or PPI (selected cases). Use. Reduce laryngopharyngeal reflux that can worsen otitis or airway symptoms. Mechanism. Gastric acid reduction. Safety. Shortest effective duration; monitor. Evidence. FDA labels for individual agents; clinician-directed. FDA Access Data

15. Antihistamine eyedrops (if allergic component)
    Class. Antihistamine/mast-cell stabilizers. Use. Ocular itch that complicates care of fragile ocular surfaces. Mechanism. H1 blockade/stabilization. Caution. Avoid preservatives if surface disease is significant. Evidence. FDA labels for specific products; individualized. FDA Access Data

16. Saline nasal irrigations (adjunct)
    Class. Non-drug device/solution. Use. Support nasal hygiene pre/post ENT procedures. Mechanism. Mechanical clearance. Evidence. Supportive; not an FDA-approved drug. NCBI

17. Antibiotic ear drops—quinolone class
    Class. Fluoroquinolones (ofloxacin/ciprofloxacin otic). Use. External/middle ear infections with tubes or perforation. Mechanism. As above. Evidence. FDA labels (examples cited above). FDA Access Data

18. Perioperative antibiotic prophylaxis (case-by-case)
    Class. According to procedure and local patterns. Use. Reduce surgical site infection risk. Mechanism. Pre-incision coverage reduces contamination. Evidence. Follow surgical/antibiotic stewardship guidelines; drug labels inform dosing/safety. FDA Access Data

19. Lubricating ophthalmic ointments/gels (nonprescription class)
    Class. Ocular surface lubricants. Use. Nighttime surface protection with exposure risk. Mechanism. Barrier lubrication. Evidence. OTC monographs/clinical practice; not Rx labels. Use under clinician guidance in pediatrics. MedlinePlus

20. Topical steroid-antibiotic combinations (selected cases)
    Class. As in item 9, used only with clear indications and close follow-up. Mechanism. Combined anti-inflammatory/antimicrobial effects. Risks. IOP rise, delayed healing. Evidence. FDA labels. FDA Access Data

---

Dietary Molecular Supplements

Always discuss supplements with clinicians, especially for children and before surgery.

1. Omega-3 fatty acids (DHA/EPA) — May support tear-film stability and ocular surface comfort in exposure/duct disease; typical adult dosing 1–2 g/day combined DHA/EPA with meals (pediatric dosing individualized). Mechanism: anti-inflammatory lipid mediators that modulate meibomian and lacrimal function; evidence in ocular surface disease is mixed—use as adjunct. MedlinePlus

2. Vitamin A (within safe limits) — Supports corneal/retinal epithelial health; dosing must avoid toxicity and be pediatric-tailored. Mechanism: retinoid signaling in epithelial differentiation. Use only if deficiency suspected/confirmed. MedlinePlus

3. Vitamin D — General skeletal/immune support; individualized dosing to reach sufficient serum 25(OH)D. Mechanism: nuclear receptor modulation; possible innate-immune effects. globalgenes.org

4. Vitamin C — Cofactor for collagen synthesis; may support wound healing after skin/oral procedures within recommended dietary limits. Mechanism: pro-collagen hydroxylation. globalgenes.org

5. Zinc — Cofactor for epithelial repair and immune function; keep within RDA to avoid copper deficiency. Mechanism: enzymatic cofactor, wound-healing pathways. globalgenes.org

6. Probiotics (strain-specific) — Gut-immune modulation may reduce antibiotic-associated diarrhea during ENT/ocular antibiotic courses; choose pediatric-studied strains. Mechanism: barrier and competitive exclusion. globalgenes.org

7. Lutein/zeaxanthin — Antioxidants concentrated in macula; adjunct for general eye health (evidence for specific BOFS outcomes is lacking). Mechanism: blue-light filtering, oxidative stress reduction. MedlinePlus

8. Collagen/gelatin protein support — Assures adequate substrates during post-op healing as part of a balanced diet; not disease-specific. Mechanism: provides amino acids for matrix repair. globalgenes.org

9. Hydration/electrolytes — Adequate fluids around surgeries and with fever/infections to support mucosal function and tear film. Mechanism: maintains surface hydration and systemic perfusion. NCBI

10. Folic acid (dietary adequacy) — Supports general growth and red-cell production; use standard age-appropriate amounts unless otherwise indicated. Mechanism: one-carbon metabolism. globalgenes.org

---

Drugs as immunity-booster / regenerative / stem-cell

There are no approved “immunity-boosting,” regenerative, or stem-cell drugs for BOFS. The items below explain why they are not indicated and what responsible care looks like.

1. Systemic corticosteroids (e.g., prednisolone) — Not an immune booster; used short-term for inflammatory indications, not to “cure” BOFS. Dosing is condition-specific; risks include adrenal suppression, infection, and glucose effects. Mechanism: broad anti-inflammatory gene regulation. FDA Access Data+1

2. Topical ophthalmic steroids (prednisolone acetate) — Role is targeted anti-inflammatory control after eye surgery or surface inflammation; not regenerative. Dose/frequency per ophthalmologist with IOP monitoring. Mechanism: phospholipase A2 inhibition. FDA Access Data

3. Growth factors/biologics (not approved for BOFS) — Experimental agents aimed at regeneration have no FDA-approved indication for BOFS-related anomalies. Families should avoid unproven stem-cell clinics. Mechanism: theoretical tissue signaling; evidence lacking in BOFS. globalgenes.org

4. Stem-cell “therapies” marketed directly to consumers — Not approved for BOFS; safety/efficacy unproven and may be dangerous. No dosage/indication exists for BOFS. Mechanism claims are speculative. globalgenes.org

5. Immunostimulant supplements — Over-the-counter products marketed to “boost immunity” have no disease-specific role; dosing is not established for BOFS. Balanced nutrition and vaccines per schedule are safer, evidence-based paths. globalgenes.org

6. Platelet-rich plasma/biologic injectables — Not standard for BOFS anomalies; no approved indications for craniofacial malformations in this syndrome. Use only within clinical trials/approved indications. globalgenes.org

---

Surgeries

1. Excision/repair of branchial skin lesions or sinus tracts
   Why. To remove persistent, infected, or weeping lesions and restore skin integrity. Procedure. Preoperative mapping, complete tract excision, layered closure; often delayed until tissue is optimal for healing. NCBI

2. Lacrimal (tear-duct) procedures
   Why. Treat nasolacrimal obstruction causing tearing/infection. Procedure. Probing/irrigation in infancy or dacryocystorhinostomy in persistent cases; sometimes silicone intubation. MedlinePlus

3. Cleft lip/palate repair or correction of “pseudocleft”
   Why. Improve feeding, speech, and facial symmetry. Procedure. Timed repairs (lip in infancy; palate before key speech milestones), possible alveolar bone grafting later. NCBI

4. Ocular procedures (e.g., cataract extraction, coloboma-related repairs, tarsorrhaphy if exposure)
   Why. Protect or restore vision and corneal health. Procedure. Standard pediatric ophthalmic techniques individualized to anatomy and risk. MedlinePlus

5. Ear procedures/hearing devices (e.g., tympanostomy tubes, ossicular reconstruction, bone-anchored systems)
   Why. Treat recurrent otitis media, conductive loss, or structural issues. Procedure. ENT-led surgery or implantation with audiology fitting and follow-up. NCBI

---

Preventions

1. Routine vaccinations and infection-control hygiene to reduce ENT/eye infection burden. globalgenes.org

2. Eye-safety practices (avoid rubbing, use protective eyewear when appropriate) to protect vulnerable corneas. MedlinePlus

3. Early treatment of conjunctivitis/blepharitis to prevent scarring or vision loss. MedlinePlus

4. Regular dental and orthodontic care around cleft/palatal issues. NCBI

5. Hearing checks at recommended intervals to avoid missed language windows. NCBI

6. Sun and skin protection on repaired/involved skin. NCBI

7. Safe feeding strategies taught by therapists to limit aspiration. NCBI

8. Adherence to follow-ups with genetics/ENT/ophthalmology/dentistry. NCBI

9. Perioperative planning (airway and bleeding risk discussion) before any surgery. NCBI

10. Genetic counseling for family planning to understand recurrence risk and options. NCBI

---

When to see doctors

• An infant has constant tearing, pus, eyelid redness, or light sensitivity—possible tear-duct blockage or infection. MedlinePlus

• There is a new or worsening eye pain, corneal redness, or vision blur—possible keratitis/ulcer needing urgent drops. FDA Access Data

• Ear drainage, fever, or sudden hearing change occurs—may need ear-drop antibiotics or further ENT care. FDA Access Data

• Skin lesions around the neck/ear are weeping, foul-smelling, or rapidly enlarging—evaluate for infection and surgical planning. NCBI

• Feeding trouble, choking, or poor weight gain—feeding therapy and cleft team review. NCBI

• Any signs of kidney problems (swelling, abnormal urine) or if advised for screening ultrasound. Wikipedia

---

What to eat and what to avoid

• Eat: soft, nutrient-dense foods post-oral surgeries (yogurt, eggs, purees) to protect repairs and maintain calories. Avoid: hard, sharp, or very hot foods soon after surgery. NCBI

• Eat: balanced meals with fruits/vegetables, lean protein, whole grains to support growth/healing. Avoid: excessive sugary snacks that worsen dental risk around cleft areas. NCBI

• Drink: plenty of water; consider room-humidification to help eyes/nasal passages. Avoid: dehydration, which worsens mucosal dryness. MedlinePlus

• Consider: omega-3-rich fish twice weekly (or clinician-approved supplements). Avoid: unregulated “mega-dose” supplements. MedlinePlus

• For reflux-prone children: smaller, more frequent meals as guided by clinicians. Avoid: late heavy meals if reflux worsens ENT symptoms. NCBI

---

Frequently Asked Questions

1. Is BOFS curable?
   No. BOFS is genetic. Treatment focuses on protecting vision and hearing, repairing structural issues (like cleft or branchial lesions), and supporting development across childhood into adulthood. NCBI

2. Which gene is involved?
   Most cases involve TFAP2A, which encodes the transcription factor AP-2α, a key regulator in craniofacial and ocular development. MedlinePlus

3. How is BOFS inherited?
   Usually autosomal dominant. An affected person has a 50% chance to pass it on; de novo variants also occur. Genetic counseling is recommended. NCBI

4. How is the diagnosis confirmed?
   By clinical features plus molecular testing showing a pathogenic TFAP2A variant. NCBI

5. What eye problems can occur?
   Microphthalmia, coloboma, cataract, refractive error, and nasolacrimal duct obstruction are typical; prompt ophthalmology care helps protect sight. MedlinePlus

6. What facial and oral findings are typical?
   A true cleft lip/palate or a “pseudocleft,” broad nasal tip, and other craniofacial differences may occur, often requiring staged surgical and orthodontic care. NCBI

7. Is hearing loss common?
   Conductive loss from outer/middle-ear anomalies is common; rarely, inner-ear loss occurs. Early audiology is key. NCBI

8. Are kidneys affected?
   Some individuals have renal anomalies; baseline ultrasound is reasonable when recommended. Wikipedia

9. What specialists should we see?
   Genetics, ophthalmology, ENT/audiology, craniofacial surgery, dentistry/orthodontics, speech-language therapy, and nephrology when indicated. NCBI

10. Are there approved drugs that fix BOFS?
    No disease-modifying drugs exist. Medicines treat infections or inflammation, and labels guide safe dosing. FDA Access Data+1

11. Is gene therapy available?
    Not currently for BOFS. Research continues to identify new TFAP2A variants and mechanisms. sciencedirect.com+1

12. Can BOFS be mild?
    Yes. Expression varies greatly—even within families. Some have subtle skin findings; others need multiple surgeries. orpha.net

13. What about school support?
    Children often benefit from IEP/504 accommodations for hearing/vision differences and medical absences. NCBI

14. Will my child need many surgeries?
    Needs vary. Many children require staged procedures (tear-duct, cleft/palate, branchial lesion repair), timed with development and safety. NCBI

15. Where can we learn more?
    GeneReviews, MedlinePlus Genetics, Orphanet, NORD, and GARD provide reliable overviews and testing information. NCBI+4NCBI+4MedlinePlus+4

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 02, 2025.